

ESRD Special Project

**Developing Clinical Performance Measures for the Care of
Patients with End Stage Renal Disease**

Phase II:

2000 Study of ESRD Clinical Performance Measures: Reliability Report

Deliverable #23 Reliability Testing Report on the 2000 CPMs Data Collection

January 19, 2001

Submitted to:

Mary Beth Ribar
Acute & Chronic Disease
Management Division
QMHAG, OCSQ
Health Care Financing Administration
7500 Security Boulevard, S3-02-01
Baltimore, MD 21244

Nancy Tollison, Project Officer
Health Care Financing Administration
Region X
2201 6th Avenue, MS/RX-42
Seattle, WA 98121

Submitted by:

Jonathan Sugarman, MD, MPH, Project Director
Naomi Maxey, Project Coordinator
Lisa Zhao, MS, Data Analyst
PRO-West, A Professional Review Organization
10700 Meridian Avenue North, Suite 100
Seattle, WA 98133

This material was prepared by PRO-West under a contract with the Health Care Financing Administration (HCFA). The contents presented do not necessarily reflect HCFA policy.

PRO-West Document Number 6SOW-WA-ESRD-01-03(PW0224 01/00)

Table of Contents

Contents

Introduction	1
Background.....	1
Project Methods	1
Statistical Methods	1
Agreement Rates.....	2
Concurrence.....	2
Kappa Statistics.....	2
T-Test statistics Based on Means	2
Data Collection.....	2
Sample and Measures: Hemodialysis CPMs	3
Sample and Measures: Peritoneal dialysis CPMs.....	3
Sample and Measures: Hemodialysis Facility Forms	4
Results.....	4
Hemodialysis CPMs.....	4
Peritoneal Dialysis CPMs.....	5
Hemodialysis Facility Forms	5
Conclusions	6

Tables

Table 1: Calculation of data concurrence	7
Table 2: Comparison of categorical data abstracted by dialysis facility staff to categorical data re-abstracted by ESRD Network staff for selected hemodialysis measures (excluding measures related to vascular access).....	8

Table 3: Comparison of means for continuous data abstracted by dialysis facility staff to continuous data re-abstracted by ESRD Network staff for selected hemodialysis measures (excluding measures related to vascular access).....	9
Table 4: Reported Kt/V [Question 16I].....	11
Table 5: Method used to calculate the reported Kt/V [Question 16J]	11
Table 6: Hemoglobin \geq 9gm/dL [Question 15A]	12
Table 7: Hemoglobin \geq 11gm/dL [Question 15A].....	12
Table 8: Transferrin saturation \geq 20% [Question 15F]	12
Table 9: Serum ferritin concentration \geq 100 ng/dL [Question 15E].....	12
Table 10: Epoetin dosage prescription (Y/N) [Question 15B]	13
Table 11: Prescribed route of epoetin administration [Question 15D]	13
Table 12: Serum albumin values (\geq 3.5/3.2 gm/dL by BCG/BCP methods) [Question 17A].....	14
Table 13: Laboratory method used to measure serum albumin in Table 12 [Question 17B]	14
Table 14: The type of access used on the last hemodialysis session on or between October 1, 1999, and December 31, 1999 [Question 18A]	15
Table 15: Reason for catheter, if used for access between October 1, 1999, and December 31, 1999 [Question 18B1]	16
Table 16: Catheter duration (\geq 90 days), if used for access between October 1, 1999, and December 31, 1999 [Question 18B2]	17
Table 17: Presence of routine monitoring for stenosis, when synthetic grafts, bovine grafts, or AV fistulas were used for access between October 1, 1999, and December 31, 1999 [Question 18C1]	17
Table 17a-e: The routine stenosis monitoring method used between October 1, 1999, and December 31, 1999, when synthetic grafts, bovine grafts, or AV fistulas were used for access [Question 18C2]	18-20
Table 18: The type of access used at the initiation (re-initiation) of the first time hemodialysis, if between January 1, 1999 – August 31, 1999 [Question 19A]	20

Table 19: The type of access used 90 days after the date in Table 18 during the initiation (re-initiation) of hemodialysis, if between January 1, 1999 – August 31, 1999 [Question 19C]	21
Table 20: Limb amputation (Y/N) [Question 13].....	21
Table 21: Number of scheduled hemodialysis times per week [Question 16A].....	22
Table 22: Agreement rate of data abstracted by dialysis facility staff to data re-abstracted by ESRD Network staff for selected hemodialysis measures.....	22
Table 23: Comparison of categorical data abstracted by dialysis facility staff to categorical data re-abstracted by ESRD Network staff for selected peritoneal dialysis measures.....	23
Table 24: Comparison of means for continuous data abstracted by dialysis facility staff to continuous data re-abstracted by ESRD Network staff for selected peritoneal dialysis measures.....	24
Table 25: Reported Kt/V [Question 18D]	25
Table 26: Method used to calculate the V in Kt/V_{urea} [Question 18E].....	25
Table 27: Reported weekly creatinine clearance [Question 18F].....	26
Table 28: Creatinine clearance corrected for body surface area, using standard methods (Y/N) [Question 18G]	26
Table 29: Hemoglobin ≥ 9 gm/dL [Question 15A].....	26
Table 30: Hemoglobin ≥ 11 gm/dL [Question 15A].....	26
Table 31: Transferrin saturation $\geq 20\%$ [Question 15F].....	27
Table 32: Serum ferritin concentration ≥ 100 g/mL [Question 15E].....	27
Table 33: Epoetin dose prescription (Y/N) [Question 15B].....	27
Table 34: Prescribed route of epoetin administration [Question 15D]	27
Table 35: Serum albumin values ($\geq 3.5/3.2$ gm/dL by BCG/BCP methods) [Question 16A].....	28
Table 36: Laboratory method used to measure serum albumin in Table 35 [Question 16B]	28

Table 37: Number of scheduled dialysis days per week [Question 19A].....	28
Table 38: Total number of exchanges per 24 hours for CAPD patients [Question 19B2]	29
Table 39: Total number of dialysis exchanges during the nighttime for cycler patients [Question 19C3b]	29
Table 40: Total number of dialysis exchanges during the daytime for cycler patients [Question 19C4b]	30
Table 41: Prescription changed (Y/N) [Question 19E2]	30
Table 42: Limb amputation (Y/N) [Question 13].....	31
Table 43: Agreement rate of data abstracted by dialysis facility staff to data re-abstracted by ESRD Network staff for selected peritoneal dialysis measures	31
Table 44: Do facilities have a written policy for the timing of the post-BUN sample collection? [Question 1].....	32
Table 45: Facilities' written policy regarding post-dialysis BUN sampling [Question 1]	33
Table 46: Facilities' compliance with written policy (internal audit) regarding post-dialysis BUN sampling [Question 2]	34
Table 47: Facilities that re-used dialyzers from October 1, 1998, to December 31, 1998 [Question 3].....	34
Table 48: Facilities that pre-volumed 95-100% of dialyzers intended for reuse [Question 3]	35
Table 49: Facilities that pre-volumed <95% of dialyzers intended for reuse [Question 3]	35
Table 50: Facilities that used batch testing and/or of an average TCV for a group of hemodialyzers to infer TCV [Question 3].....	36
Table 51: Facilities that used the manufacturer's product information to infer TCV [Question 3]	36